Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Evaluate Weight Gain Using 2 Different Formulations of Megestrol Acetate Oral Suspension for AIDS-Related Weight Loss
This study has been completed.
Study NCT00637572 Information provided by Par Pharmaceutical, Inc.
First Received: March 11, 2008 Last Updated: April 1, 2008
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
HIV Infections
Unintended Weight Loss
Cachexia
Anorexia
AIDS Wasting Syndrome
HIV Wasting Syndrome
Additional conditions recognized in this trial
Acquired Immunodeficiency Syndrome
Body Weight
Infection
Syndrome
Wasting Syndrome
Weight Gain
Weight Loss
More general conditions related to this trial
Body Weight Changes
Disease
Emaciation
Immune System Diseases
Immunologic Deficiency Syndromes
Lentivirus Infections
Metabolic Diseases
Nutrition Disorders
Pathologic Processes
Retroviridae Infections
RNA Virus Infections
Sexually Transmitted Diseases
Sexually Transmitted Diseases, Viral
Signs and Symptoms
Signs and Symptoms, Digestive
Slow Virus Diseases
Virus Diseases
Additional drug interventions recognized in this trial
Megestrol
Megestrol Acetate
More general drug interventions related to this trial
Antineoplastic Agents
Antineoplastic Agents, Hormonal
Appetite Stimulants
Central Nervous System Agents
Central Nervous System Stimulants
Contraceptive Agents
Contraceptive Agents, Female
Contraceptives, Oral
Contraceptives, Oral, Synthetic
Pharmacologic Actions
Physiological Effects of Drugs
Reproductive Control Agents
Therapeutic Uses
Sponsors listed in this trial
Par Pharmaceutical, Inc.
Quintiles
Back to top of Main Content
